1-4 of 4
Julie Lisano, PharmD
Close
Sort by
Journal Articles

Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

Tycel J. Phillips, MD, Kristina Yu-Isenberg, PhD MPH, RPh, Nicholas Liu, PharmD, Andy Surinach, MPH, Carlos Flores, MPH, Julie Lisano, PharmD, Michelle A. Fanale, MD, John M. Burke, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-140534
Published: 2020
Journal Articles

Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

John M. Burke, MD, Nicholas Liu, PharmD, Kristina Yu-Isenberg, PhD MPH, RPh, Michelle A. Fanale, MD, Andy Surinach, MPH, Carlos Flores, MPH, Julie Lisano, PharmD, Tycel J. Phillips, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-140832
Published: 2020
Journal Articles

Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma

Anne Shah, MS, Allison Petrilla, MPH, Mayvis Rebeira, PhD, Joseph Feliciano, PharmD, Thomas W. LeBlanc, MDMA,MHS, Julie Lisano, PharmD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3492.
https://doi.org/10.1182/blood-2019-130973
Published: 2019
Journal Articles

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL

Sairah Ahmed, MD, Julie Lisano, PharmD, Trevor Newhook, MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 4054.
https://doi.org/10.1182/blood-2019-121523
Published: 2019